(Q24803894)

2

0 references

Tatsuya Toyama

3

0 references

Hiroshi Sugiura

4

0 references

Zhenhuan Zhang

5

0 references

Shunzo Kobayashi

6

0 references

Hirotaka Iwase

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7

0 references

language of work or name

English

0 references

publication date

2004

0 references

published in

Breast Cancer Research

0 references

volume

6

0 references

issue

1

0 references

page(s)

R24-30

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Analysis of oncogenes and tumor suppressor genes in human breast cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=314452

Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer

28 November 2018

1 reference

12 December 2020

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

1 reference

12 December 2020

Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast

1 reference

12 December 2020

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

12 December 2020

p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry

1 reference

12 December 2020

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

12 December 2020

Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer

1 reference

12 December 2020

p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques

1 reference

12 December 2020

p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis

1 reference

12 December 2020

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer

1 reference

12 December 2020

Clinical significance of bcl-2 gene expression in human breast cancer tissues

1 reference

12 December 2020

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

12 December 2020

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases

1 reference

12 December 2020

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

12 December 2020

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

12 December 2020

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR738

1 reference

Dimensions Publication ID

1002660989

0 references

1 reference

1 reference

PubMed publication ID

14680497

1 reference